From the Program of Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA; the Program of Clinical Statistics, Fred Hutchinson Cancer Research Center, Seattle, WA; the Department of Medicine, University of Washington, Seattle; and the Department of Laboratory Medicine, University of Washington, Seattle.
Prophylactic fluconazole prevents candidiasis; however, this drug has no activity against molds. We performed a randomized trial to determine whether prophylactic itraconazole prevents invasive mold infections (IMIs). A total of 304 patients receiving allogeneic stem cell transplants (SCT) were randomized to receive fluconazole (400 mg/d) or itraconazole (oral solution 2.5 mg/kg 3 times daily, or intravenous 200 mg daily) for 180 days after SC transplantation, or until 4 weeks after discontinuation of graft-versus-host disease (GVHD) therapy. Proven or probable invasive fungal infections (IFI) were evaluated by intent-to-treat and "on-treatment" analyses. More patients in the itraconazole arm developed hepatotoxicities, and more patients were discontinued from itraconazole because of toxicities or gastrointestinal (GI) intolerance (36% versus 16%, P < .001). Intent-to-treat analysis demonstrated no difference in the incidence of IFI during the intended study period (fluconazole 16% versus itraconazole 13%, P = .46); however, fewer patients in the itraconazole arm developed IFI on treatment (fluconazole 15% versus itraconazole 7%, P = .03). Itraconazole provided better protection against IMI (fluconazole 12% versus itraconazole 5%, P = .03), but similar protection against candidiasis (3% versus 2%, P = .69). There was no difference in overall or fungal-free survival. Itraconazole appears to prevent IMI in the subset of patients who tolerate the drug; however, toxicities and poor tolerability limit its success as prophylactic therapy.
This article has been cited by other articles:
 |
|
 |
|
  Minerva BMJ, March 6, 2004; 328(7439): 592 - 592. [Full Text] [PDF] |
|
|
| |||||
|
|
 |
|
 K. A. Marr, W. Leisenring, F. Crippa, J. T. Slattery, L. Corey, M. Boeckh, and G. B. McDonald Cyclophosphamide metabolism is affected by azole antifungals Blood, February 15, 2004; 103(4): 1557 - 1559. [Abstract] [Full Text] [PDF] |
|
|
| |||||
Related Articles in Blood Online :
- Fungal infection in hemato-oncologic patients: better to prevent than to treat?.
Jan W. van't Wout and Jaap T. van Dissel Blood 2004 103: 1182-1183.[Full Text]
A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis
A novel SHP-1/Grb2–dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling
A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation
Allergen exposure–induced differences in CD34+ cell phenotype: relationship to eosinophilopoietic responses in different compartments
And a final message from antithrombin
Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
Anti-CD40L: biology and therapy in ITP
BUBR1 deficiency results in abnormal megakaryopoiesis
Cell adhesion: a partner for many